A randomized placebo-controlled trial of tideglusib vs. placebo in the treatment of adolescents with ASD

Medication Clinical Trials


Summary

Currently conducting clinical trials to investigate whether a drug called tideglusib helps to improve symptoms of Autism Spectrum Disorder, specifically social engagement, social function, and repetitive behaviours. 


Researcher(s)

Evdokia Anagnostou, MD

Participate in this study

Have you been diagnosed with an autism spectrum disorder?  Do you have social difficulties and/or repetitive behaviours?  You may be eligible to participate in a clinical trial of a medication called tideglusib.

Who can participate

Adolescents between 12-17 years of age with a diagnosis of an autism spectrum disorder (ASD, autism, PDD-NOS, or Asperger's syndrome)

What's Involved

The trial will last a total of 16 weeks (4 months) and involves taking either tideglusib or a placebo dissolve in water every morning for 12 weeks, with a follow-up visit around 4 weeks later.  You and your child will first be asked to come in for a screening session; through talking with you and completing some assessments, we will determine if your child meets eligibility criteria.

Visits will occur at Holland Bloorview and will take place every two weeks while your child is taking the drug or placebo.  This study also has an optional continuation part, which means that if you were given placebo, you will be able to take tideglusib at the end of the four months.  The same tests and procedures will be followed that were followed during the main study.

Participants will receive a small token of appreciation in the form of a $20.00 gift card to thank them for their time.

Deadline

April 2017- Closed


Interested in participating

If you are interested in participating in this study or have additional questions, please contact Naomi Peleg at 416-425-6220 ext 3456 or npeleg@hollandbloorview.ca with your interest, and they will get back to you shortly.  Contacting us does not obligate you or your child to participate in the study.

 

Funding Agency

Brian Canada and Ontario Brain Institute

Learn more about this study